Plain-English translation of NCT07416526 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called NXT007 to see if it works better than the current standard factor VIII treatment at preventing bleeding episodes in people with hemophilia A. The study will compare how well NXT007 prevents bleeding, how safe it is, and how the body uses and responds to it compared to standard factor VIII prophylaxis (preventive treatment).
People with hemophilia A currently rely on regular factor VIII injections to prevent dangerous bleeding. This trial exists to see if this new treatment option could offer improved protection or other benefits compared to what patients are using today.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either NXT007 or your current factor VIII treatment during the main study period. You'll have regular clinic visits to receive your medication, give blood samples, and report any bleeding episodes. After the main study ends, you'll have the option to continue or switch to NXT007 in an extension period, allowing researchers to gather longer-term safety and effectiveness data.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States
Argentina
Brazil
China